

Date and Time: 26th July 2013 10:00–16:00

Minutes: Draft

Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care (partial update)

Guideline Development Group Meeting 8

Place: NCGC, 180 Great Portland Street, London

Present: Paul Stevens (Chair) PS
Serena Carville, Senior Research Fellow & Project Manager
Lilian Li (Health economist) LL
Jill Parnham (Guideline lead) JP

Ed Lamb (Clinical biochemist) EL
Robert Lewis (Nephrologist) RL
Hugh Gallagher (Nephrologist) HG
Kathryn Griffith (GP) KG
Paula D'Souza (Renal nurse) PD
Karen Jenkins (Renal nurse) KJ
Paul Kendrew (Renal pharmacist) PK
Nicholas Palmer (Lay member) NP
Paul Roderick (Professor of public health) PR
Fiona Loud (Lay member) FL
Shelagh O'Riordan (Geriatrician) SO
Ben Doak, NICE Guideline Commissioning Manager

Apologies Caroline Blaine (Research Fellow) CB

In attendance Campbell Cowan, Consultant Cardiologist (by phone for agenda item 4)
Rob Henderson, Consultant Cardiologist (by phone for agenda item 4)
Saskia Cheyne, Project manager NCGC (observing, AM only)

NICE staff	Ben Doak, (Guideline Commissioning Manager)	
------------	---------------------------------------------	--

Notes

1. Introductions and apologies. PS welcomed everyone to the meeting. No apologies had been received for today. The GDG were informed that Paula D'Souza would join the meeting after lunch due to conflicts relevant to the morning discussion points.

Declarations of Interest. All GDG members were asked to verbally declare any new declarations of interests since GDG8. Four new DOIs were noted. Rob Lewis is attending a conference on home dialysis, there may be an honoraria received, but this would be from a hospital endowment fund. Paula D'Souza attended an event sponsored by Fresenius and Amgen, but took no financial reimbursement or meals. Nick Palmer is attending a conference on holiday dialysis. Fiona Loud declared that she wrote an article for the Journal of Renal Care published July 24, 2013 about commissioning, and received a small fee. This journal previously receives small amounts of funding from pharmaceutical companies, but there is nothing specific that indicates a conflict. All agreed as declare and participate.

3. Draft working notes and NICE minutes from GDG8. The GDG discussed possible amendments. It was highlighted that tings can be corrected in the LETR discussions. The minutes were agreed as an accurate reflection of the meeting.
4. Evidence review: Antiplatelets and anticoagulants. RH and CC were welcomed to the meeting as co-opted experts for this review. The clinical evidence was presented by SC and LL presented the economic evidence. The GDG discussed draft recommendations with input from the co-opted experts.
5. Health economics: RAAS antagonists. LL presented the updated plan for economic analysis. The GDG discussed the proposal and agreed that it was not feasible to continue with plans to undertake an economic model for RAAS antagonists.
6. Evidence review: Cause of CKD. SC presented the evidence and the GDG discussed draft recommendations.
7. Any other business. The GDG group were asked to think about future research recommendations. The GDG were informed of the next meeting date and the remaining meetings.

Date, time and venue of the next meeting

GDG9: 13th September 2013, 10:00–16:00, Boardroom, NCGC offices, 180 Great Portland Street